Skip to main content

Table 1 Clinical and pathologic characteristics of 118 endometrioid endometrial cancer patients and their association to Trop-2 protein expression

From: Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma

      Trop-2 protein expression   
Variable n Score≤1 n (%) Score=2 n (%) Score=3 n(%) p value*
Age at diagnosis      
 <65 51 22 (43.1) 17 (33.3) 12 (23.5)  
      0.89
 ≥65 67 28 (41.8) 26 (38.8) 13 (19.4)  
FIGO stage(2009 criteria)      
 I-II 86 37 (43) 33 (38.4) 16 (18.6)  
      0.56
 III-IV 22 8 (36.4) 6 (27.3) 8 (36.4)  
 Unknown 10 5 (50) 4 (40) 1 (10)  
WHO grading      
 Grade 1 34 21 (61.8) 11 (32.4) 2 (5.9)  
      0.024
 Grade 2-3 84 29 (34.5) 32 (38.1) 23 (27.4)  
Myometrial invasion      
 M0+M1 55 26 (47.3) 22 (40) 7 (12.7)  
      0.08
 M2 63 24 (38.1) 21 (33.3) 18 (28.6)  
Lymph node status      
 Negative 79 35 (44.3) 28 (35.4) 16 (20.3)  
      0.69
 Positive 15 5 (33.3) 5 (33.3) 5 (33.3)  
 Unknown 24 10 (41.7) 10 (41.7) 4 (16.7)  
Cervical involvement      
 Absent 83 37 (44.6) 33 (39.8) 13 (15.7)  
 Glandular involvement 16 10 (62.5) 4 (25) 2 (12.5) <0.01$
 Stromal involvement 18 3 (16.7) 6 (33.3) 9 (50)  
 Unknown 1 0 (0) 0 (0) 1 (100)  
Adnexal involvement      
 Negative 108 45 (41.7) 42 (38.9) 21 (19.4) 0.97
 Positive 9 5 (55.6) 0 (0) 4 (44.4)  
 Unknown 1 0 (0) 1 (100) 0 (0)  
Peritoneal cytology      
 Negative 100 40 (40) 37 (37) 23 (23)  
      0.44
 Positive 8 4 (50) 2 (25) 2 (25)  
 Unknown 10 6 (60) 4 (40) 0 (0)  
Lymphovascular invasion      
 Absent 48 22 (45.8) 20 (41.7) 6 (12.5)  
      0.13
 Present 56 21 (37.5) 20 (35.7) 15 (26.8)  
 Unknown 14 7 (50) 3 (21.4) 4 (28.6)  
Adjuvant Treatment      
 None 57 31 (54.4) 20 (35.1) 6 (10.5)  
 Radiotherapy 36 12 (33.3) 13 (36.1) 11 (30.6)  
 Chemotherapy 8 3 (37.5) 1 (12.5) 4 (50.0) 0.094$
 Radiotherapy+Chemotherapy 9 2 (22.2) 5 (55.6) 2 (22.2)  
 Unknown 8 5 (62.5) 2 (25.0) 1 (12.5)  
Parity      
 Nulliparity 22 10 (45.5) 7 (31.8) 5 (22.7)  
      0.72
 Multiparity 88 34 (38.6) 35 (39.8) 19 (21.6)  
 Unknown 8 6 (75) 1 (12.5) 1 (12.5)  
Body Mass Index      
 <25 36 12 (33.3) 14 (38.9) 10 (27.8)  
      0.58
 ≥25 64 27 (42.2) 24 (37.5) 13 (20.3)  
 Unknown 18 11 (61.1) 5 (27.8) 2 (11.1)  
Hypertension      
 Negative 48 18 (37.5) 18 (37.5) 12 (25)  
      0.26
 Positive 63 27 (42.9) 24 (38.1) 12 (19)  
 Unknown 7 5 (71.4) 1 (14.3) 1 (14.3)  
Diabetes      
 Negative 96 38 (39.6) 39 (40.6) 19 (19.8)  
      0.95
 Positive 15 8 (53.3) 2 (13.3) 5 (33.3)  
 Unknown 7 4 (57.1) 2 (28.6) 1 (14.3)  
Menopausal Status      
 Premenopausal 18 7 (38.9) 5 (27.8) 6 (33.3)  
      0.33
 Postmenopausal 94 39 (41.5) 37 (39.4) 18 (19.1)  
 Unknown 6 4 (66.7) 1 (16.7) 1 (16.7)  
Smoking      
 Negative 82 29 (35.4) 35 (42.7) 18 (22)  
      0.91
 Positive 20 9 (45) 6 (30) 5 (25)  
 Unknown 16 12 (75) 2 (12.5) 2 (12.5)  
  1. * Exact Wilcoxon-Mann–Whitney test.
  2. $ Non-parametric ANOVA.
  3. Unknown values were considered as missing and therefore excluded from the statistical analysis.
\